It intervened ﬁrstly before the US District Court for the District of Columbia concerning the ongoing ‘Vitamins’ litigation, and, secondly, before the US District Court for the District of Northern California concerning the ‘Methionine’ litigation; in this case, the Commission’s stance on the non-discoverability of corporate statements submitted to the Commission within the framework of its leniency programme was conﬁrmed by the Court at ﬁnal instance.
Elle est d’abord intervenue devant la US District Court for the District of Columbia concernant l’affaire en cours Vitamines. Ensuite, devant la US District Court for the District of Northern California concernant l’affaire Méthionine; dans cette affaire, la position de la Commission concernant le caractère non divulgable des déclarations d’entreprise qui lui sont soumises dans le cadre de son programme de clémence a été conﬁrmée par le tribunal en dernière instance.